NewGenIvf Group Valuation

Is NIVF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NIVF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NIVF's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NIVF's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NIVF?

Key metric: As NIVF is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NIVF. This is calculated by dividing NIVF's market cap by their current earnings.
What is NIVF's PE Ratio?
PE Ratio	45.2x
Earnings	US$130.19k
Market Cap	US$6.61m

NIVF key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	85.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does NIVF's PE Ratio compare to its peers?

The above table shows the PE ratio for NIVF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	63.3x
IDXG Interpace Biosciences	2.5x	n/a	US$12.5m
AMS American Shared Hospital Services	4.9x	n/a	US$19.4m
LDDD Longduoduo	170.7x	n/a	US$156.0m
AONC American Oncology Network	75.1x	n/a	US$173.8m
NIVF NewGenIvf Group	45.2x	n/a	US$6.6m

Price-To-Earnings vs Peers: NIVF is good value based on its Price-To-Earnings Ratio (45.2x) compared to the peer average (63.3x).

Price to Earnings Ratio vs Industry

How does NIVF's PE Ratio compare vs other companies in the US Healthcare Industry?

5 Companies	Price / Earnings	Estimated Growth	Market Cap
THC Tenet Healthcare	4.7x	-39.2%	US$14.77b
NEUE NeueHealth	1.5x	n/a	US$41.27m
AMS American Shared Hospital Services	4.9x	n/a	US$19.37m
IDXG Interpace Biosciences	2.5x	n/a	US$12.54m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: NIVF is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the US Healthcare industry average (25.1x).

Price to Earnings Ratio vs Fair Ratio

What is NIVF's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NIVF PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	45.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NIVF's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Centene

US$29.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$58.83

-3.2%

-19.1%

Elevance Health

US$92.9b

Operates as a health benefits company in the United States.

ELV

US$400.70

-5.8%

-13.9%

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$56.05

0.4%

-17.9%